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Abstract  
Background: In a previous pilot study, we demonstrated that
 
CD8-depletion of the graft 
apparently reduced the severity of
 
AGvHD without impairing the GvL effect after peripheral 
blood
 





Aim of the study: To evaluate the effect of CD8-depletion on
 




Patients: 53 patients were randomised between CD8-depletion
 
(group 1) (n=25) and no 
manipulation (group 2) (n=28). Two patients
 
in the CD8 group were excluded for poor CD34+ 
cell count collected.
 
Diagnoses were: AML (n=3), CML-AP (n=2), MDS (n=14), MPD (n=3),
 
CLL (n=5), NHL (n=14), MM (n=8) and RCC (n=2). Median age was
 
57 (range 36–69) yrs. 
After conditioning with 2 Gy TBI
 
with (n=39) or without (n=12) fludarabine, patients received
 
PBSC from family (n=21) or unrelated (n=30) HLA-matched donors.
 
CD8-depletion was carried 
out using the Eligix system and GvHD
 
prophylaxis consisted in CyA and MMF.
 
 
Results: CD8 depletion removed 96% of CD8+ cells so that the
 
number of CD8+ cells infused 




in group 2 (p<0.0001). AGvHD of any grade was observed in
 
13 
(56%) patients in group 1 and 17 (61%) in group 2 (NS); it
 
was grade 3–4 in 1 (4%) and 5 (18%) 
patients in groups
 
1 and 2, respectively (NS). Limited and extensive CGvHD developed
 
in 3 and 
1 patients in group 1 and in 7 and 2 patients in group
 
2, respectively (NS). Nine patients in group 
1 and 12 in group
 
2 received unmanipulated DLI for poor chimerism or disease progression.
 
Eight (3 initial and 5 late) graft failures were observed in
 
group 1 and one (late) in group 2. Full 
donor chimerism was
 
achieved in 57% (group 1) and 50% (group 2) at day 100, and
 
in 73% 
(group 1) and 59% (group 2) (NS) at 1 yr. The 2-yr OS
 
and PFS rates are 55% and 43 % in group 
1 vs 59% and 46% in
 
group 2, respectively (NS). Four (17%) patients died of their
 
disease in 
group 1 vs 3 (11%) in group 2 (NS). Two patients
 




Conclusion: In vitro CD8-depletion results in higher rates of
 
graft failure after NMSCT. The 
incidence of acute and chronic
 
GvHD is not reduced but there is a trend towards reduced severity
 
of AGvHD. Relapse and survival rates are not changed by this
 
strategy.
 
 
 
